Are Colon Polyp Characteristics Really Different Between Men and Women?

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY
JGH Open Pub Date : 2025-04-10 DOI:10.1002/jgh3.70161
Guo-Jeng Tan, Sanjiv Mahadeva
{"title":"Are Colon Polyp Characteristics Really Different Between Men and Women?","authors":"Guo-Jeng Tan,&nbsp;Sanjiv Mahadeva","doi":"10.1002/jgh3.70161","DOIUrl":null,"url":null,"abstract":"<p>Colorectal cancer affects men differently from women. The sex-related differences in the incidence of colorectal cancer are well documented. The age-standardized incidence of colorectal cancer for males in Western Europe in the year 2020 was 20.0 per 100 000; whereas for women, it was 15.1 per 100 000 [<span>1</span>]. In addition to that, adult males suffer more morbidity from colorectal cancer compared with females. In a study among men with colorectal cancer attributable to high body-mass index, the age-standardized disability-adjusted life years rate (ASDR) was 31.09 years per 100 000 people (95% CI 13.36–49.47), compared with women who had an ASDR of only 23.96 years per 100 000 persons (95% CI 10.36–37.75) [<span>2</span>]. This means men lose more years to disability caused by colorectal cancer compared with women. However, it can be argued that there is no significant difference because of the 95% confidence interval overlap. This illustrates the general trend that men are more affected than women. Male patients with CRC also have a poorer survival compared with females. In a cohort study in Australia, the 15-year survival for males with Stage I disease was reported to be 56.0%, compared with a survival of 68.0% in females. A similar pattern was also seen for Stage II and Stage III disease. Only Stage IV disease had no difference in survival between males and females [<span>3</span>].</p><p>Currently, the most widely accepted paradigm for the pathogenesis of colorectal cancer is the adenoma-carcinoma sequence outlined by Fearon and Vogelstein [<span>4</span>]. This makes the detection of adenomatous polyps vital in the early detection and management of colorectal cancer. Several reports have suggested that, just like CRC, there may be gender differences in the characteristics of colon polyps. A case–control study comparing 794 patients with polyps with 708 colonoscopy-negative controls found that the male sex was significantly associated with an increase in all polyps [<span>5</span>]. Another study of 5254 subjects identified that the male gender was an independent predictor of adenomas and had a 1.55 (95% CI: 1.02–3.23) odds of developing advanced adenomas [<span>6</span>]. Not only are men more likely to have adenomas, but they are also more likely to have larger adenomas compared with women [<span>7</span>]. There are also gender differences in the location of polyps in the colon, with a study demonstrating that males have an increased 1.88 (95% CI: 1.73–2.04) odds for proximal adenoma and an increased 1.81 (95% CI: 1.67–1.96) odds for distal adenomas [<span>8</span>].</p><p>Most of the above studies were conducted in adults undergoing direct colonoscopy without prior stool test screening. Anderson and colleagues' study, as published in JGH Open [<span>9</span>], attempts to explore if the type of polyps and anatomical location of the polyps can be predicted using multi-target stool DNA (mt-sDNA) and fecal immunochemical test (FIT). Patients from the New Hampshire Colonoscopy Registry (NHCR) with either positive mt-sDNA or FIT who then have a colonoscopy were compared with patients who only have direct screening colonoscopies. The baseline demographic and clinical data showed that a positive FIT or mt-sDNA increases the yield of finding a lesion, regardless of gender, anatomical position (left-sided or right-sided lesion), or type of lesion (adenoma or serrated polyp). After statistical adjustments, mt-sDNA still performed well in all combinations, but FIT fell short in right colonic lesions for males and left colonic advance adenoma for women.</p><p>In terms of the demographic characteristics of the men and women in this study, it appears that they were not well matched. The patients with positive mt-sDNA and FIT tended to be older, were current smokers, and were consuming “blood thinners.” It is not clear whether the “blood thinners” were antiplatelet therapy or anticoagulants. There is evidence that this may not affect FIT [<span>10</span>] but the effects on mt-sDNA are still unclear. Another issue was that aspirin has been shown to reduce the long-term risk of colorectal cancer [<span>11</span>] but not the other antiplatelets or anticoagulants, so by lumping everyone together important information may have been missed, even if with adjustment by statistical analysis. Another issue in the cases without FIT or mt-sDNA were that they had a higher proportion of previous colonoscopies and a family history of CRC. So there is a possibility that patients in this group would have had lesions/polyps removed previously and this would have artificially reduced the yield of advanced lesions, when compared with subjects who had positive stool tests. There were only 1760 patients with positive stool tests compared with 68 645 patients who were screened with colonoscopy only. This created an imbalance that might have rendered some of the results invalid. This was reflected by the narrower confidence intervals for the colonoscopy-only screening group compared with those with positive stool tests. Another limitation of the study was the division of patients with positive stool tests into smaller categories, which may have led to Type I statistical errors.</p><p>In summary, the study by Anderson et al. have shown that positive stool tests correlate more with right-sided advanced lesions in females but not in males. However, when positive stool tests were used to predict right-sided advanced adenomas, they were not able to do so in both males and females. Mt-sDNA appears to predict right-sided advanced serrated polyps in both males and females, but FIT can only do so for females. The study does show some gender differences in the anatomical position of colonic polyps in patients with a positive stool test. However, the differences are small, and even in combinations that do show a difference, the wide and overlapping 95% confidence intervals seem to preclude any daily practical use when compared to a protocol-driven colonoscopy done for the correct indication and with good bowel preparation. In closing, we would like to reiterate that the differences between males and females in colorectal cancer are well-established and well-recognized. There are also known gender differences concerning polyps; however, we feel that this study was not able to demonstrate how positive stool tests can predict this difference as clearly as the authors would have liked.</p><p>Prof. Sanjiv Mahadeva is an Editorial Board member of <i>JGH Open</i> and a co-author of this article. To minimize bias, he was excluded from all editorial decision-making related to the acceptance of this article for publication.</p>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"9 4","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgh3.70161","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JGH Open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgh3.70161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Colorectal cancer affects men differently from women. The sex-related differences in the incidence of colorectal cancer are well documented. The age-standardized incidence of colorectal cancer for males in Western Europe in the year 2020 was 20.0 per 100 000; whereas for women, it was 15.1 per 100 000 [1]. In addition to that, adult males suffer more morbidity from colorectal cancer compared with females. In a study among men with colorectal cancer attributable to high body-mass index, the age-standardized disability-adjusted life years rate (ASDR) was 31.09 years per 100 000 people (95% CI 13.36–49.47), compared with women who had an ASDR of only 23.96 years per 100 000 persons (95% CI 10.36–37.75) [2]. This means men lose more years to disability caused by colorectal cancer compared with women. However, it can be argued that there is no significant difference because of the 95% confidence interval overlap. This illustrates the general trend that men are more affected than women. Male patients with CRC also have a poorer survival compared with females. In a cohort study in Australia, the 15-year survival for males with Stage I disease was reported to be 56.0%, compared with a survival of 68.0% in females. A similar pattern was also seen for Stage II and Stage III disease. Only Stage IV disease had no difference in survival between males and females [3].

Currently, the most widely accepted paradigm for the pathogenesis of colorectal cancer is the adenoma-carcinoma sequence outlined by Fearon and Vogelstein [4]. This makes the detection of adenomatous polyps vital in the early detection and management of colorectal cancer. Several reports have suggested that, just like CRC, there may be gender differences in the characteristics of colon polyps. A case–control study comparing 794 patients with polyps with 708 colonoscopy-negative controls found that the male sex was significantly associated with an increase in all polyps [5]. Another study of 5254 subjects identified that the male gender was an independent predictor of adenomas and had a 1.55 (95% CI: 1.02–3.23) odds of developing advanced adenomas [6]. Not only are men more likely to have adenomas, but they are also more likely to have larger adenomas compared with women [7]. There are also gender differences in the location of polyps in the colon, with a study demonstrating that males have an increased 1.88 (95% CI: 1.73–2.04) odds for proximal adenoma and an increased 1.81 (95% CI: 1.67–1.96) odds for distal adenomas [8].

Most of the above studies were conducted in adults undergoing direct colonoscopy without prior stool test screening. Anderson and colleagues' study, as published in JGH Open [9], attempts to explore if the type of polyps and anatomical location of the polyps can be predicted using multi-target stool DNA (mt-sDNA) and fecal immunochemical test (FIT). Patients from the New Hampshire Colonoscopy Registry (NHCR) with either positive mt-sDNA or FIT who then have a colonoscopy were compared with patients who only have direct screening colonoscopies. The baseline demographic and clinical data showed that a positive FIT or mt-sDNA increases the yield of finding a lesion, regardless of gender, anatomical position (left-sided or right-sided lesion), or type of lesion (adenoma or serrated polyp). After statistical adjustments, mt-sDNA still performed well in all combinations, but FIT fell short in right colonic lesions for males and left colonic advance adenoma for women.

In terms of the demographic characteristics of the men and women in this study, it appears that they were not well matched. The patients with positive mt-sDNA and FIT tended to be older, were current smokers, and were consuming “blood thinners.” It is not clear whether the “blood thinners” were antiplatelet therapy or anticoagulants. There is evidence that this may not affect FIT [10] but the effects on mt-sDNA are still unclear. Another issue was that aspirin has been shown to reduce the long-term risk of colorectal cancer [11] but not the other antiplatelets or anticoagulants, so by lumping everyone together important information may have been missed, even if with adjustment by statistical analysis. Another issue in the cases without FIT or mt-sDNA were that they had a higher proportion of previous colonoscopies and a family history of CRC. So there is a possibility that patients in this group would have had lesions/polyps removed previously and this would have artificially reduced the yield of advanced lesions, when compared with subjects who had positive stool tests. There were only 1760 patients with positive stool tests compared with 68 645 patients who were screened with colonoscopy only. This created an imbalance that might have rendered some of the results invalid. This was reflected by the narrower confidence intervals for the colonoscopy-only screening group compared with those with positive stool tests. Another limitation of the study was the division of patients with positive stool tests into smaller categories, which may have led to Type I statistical errors.

In summary, the study by Anderson et al. have shown that positive stool tests correlate more with right-sided advanced lesions in females but not in males. However, when positive stool tests were used to predict right-sided advanced adenomas, they were not able to do so in both males and females. Mt-sDNA appears to predict right-sided advanced serrated polyps in both males and females, but FIT can only do so for females. The study does show some gender differences in the anatomical position of colonic polyps in patients with a positive stool test. However, the differences are small, and even in combinations that do show a difference, the wide and overlapping 95% confidence intervals seem to preclude any daily practical use when compared to a protocol-driven colonoscopy done for the correct indication and with good bowel preparation. In closing, we would like to reiterate that the differences between males and females in colorectal cancer are well-established and well-recognized. There are also known gender differences concerning polyps; however, we feel that this study was not able to demonstrate how positive stool tests can predict this difference as clearly as the authors would have liked.

Prof. Sanjiv Mahadeva is an Editorial Board member of JGH Open and a co-author of this article. To minimize bias, he was excluded from all editorial decision-making related to the acceptance of this article for publication.

男性和女性结肠息肉的特征真的不同吗?
结直肠癌对男性和女性的影响不同。结直肠癌发病率的性别差异已被充分证明。2020年西欧男性结直肠癌的年龄标准化发病率为20.0 / 10万;而女性则为15.1 / 10万。除此之外,成年男性比女性更易患结直肠癌。在一项对高体重指数导致的男性结直肠癌患者的研究中,年龄标准化残疾调整生命年率(ASDR)为每10万人31.09年(95% CI 13.36-49.47),而女性ASDR仅为每10万人23.96年(95% CI 10.36-37.75)。这意味着与女性相比,男性因结直肠癌导致的残疾寿命更长。但是,由于95%置信区间重叠,可以认为没有显著差异。这说明了男性比女性受影响更大的总体趋势。与女性相比,男性结直肠癌患者的生存率也较低。在澳大利亚的一项队列研究中,据报道,患有I期疾病的男性15年生存率为56.0%,而女性的生存率为68.0%。在II期和III期疾病中也发现了类似的模式。只有IV期疾病在男性和女性之间的生存率没有差异。目前,最被广泛接受的结直肠癌发病机制范式是Fearon和Vogelstein bbb概述的腺瘤-癌序列。这使得腺瘤性息肉的检测在结直肠癌的早期发现和治疗中至关重要。一些报道表明,就像结直肠癌一样,结肠息肉的特征可能存在性别差异。一项病例对照研究比较了794名息肉患者和708名结肠镜检查阴性的对照组,发现男性与所有息肉bbb的增加显著相关。另一项涉及5254名受试者的研究发现,男性性别是腺瘤的独立预测因子,其发展为晚期腺瘤的几率为1.55 (95% CI: 1.02-3.23)。与女性相比,男性不仅更容易患腺瘤,而且更容易患较大的腺瘤。结肠息肉的位置也存在性别差异,一项研究表明,男性近端腺瘤的发生率增加1.88 (95% CI: 1.73-2.04),远端腺瘤[8]的发生率增加1.81 (95% CI: 1.67-1.96)。上述大多数研究都是在没有事先进行粪便检查筛查的情况下进行直接结肠镜检查的成年人中进行的。Anderson及其同事的研究发表在JGH Open b[9]上,他们试图通过多靶点粪便DNA (mt-sDNA)和粪便免疫化学测试(FIT)来预测息肉的类型和息肉的解剖位置。来自新罕布什尔结肠镜检查登记处(NHCR)的mt-sDNA或FIT阳性患者随后进行结肠镜检查,与仅进行直接筛查结肠镜检查的患者进行比较。基线人口统计学和临床数据显示,FIT或mt-sDNA阳性增加了发现病变的几率,与性别、解剖位置(左侧或右侧病变)或病变类型(腺瘤或锯齿状息肉)无关。经统计调整后,mt-sDNA在所有组合中仍然表现良好,但FIT在男性右结肠病变和女性左结肠晚期腺瘤中表现不佳。就这项研究中男性和女性的人口统计学特征而言,他们似乎并没有很好地匹配。mt-sDNA和FIT呈阳性的患者往往年龄较大,目前吸烟,正在服用“血液稀释剂”。目前尚不清楚“血液稀释剂”是抗血小板治疗还是抗凝血剂。有证据表明,这可能不会影响FIT[10],但对mt-sDNA的影响仍不清楚。另一个问题是,阿司匹林已被证明可以降低患结肠直肠癌的长期风险,但其他抗血小板或抗凝血剂却没有效果,因此,将所有人混为一谈可能会遗漏重要信息,即使经过统计分析调整也是如此。在没有FIT或mt-sDNA的病例中,另一个问题是他们有更高比例的结肠镜检查和CRC家族史。所以有可能这组患者之前已经切除了病变/息肉,这将人为地减少晚期病变的产生,与粪便测试呈阳性的受试者相比。只有1760例患者粪便检查呈阳性,而仅进行结肠镜检查的患者有68645例。这造成了一种不平衡,可能导致一些结果无效。这反映在仅进行结肠镜检查的筛查组与粪便检查呈阳性的筛查组的置信区间较窄。 该研究的另一个局限性是将粪便检测呈阳性的患者划分为较小的类别,这可能导致I型统计误差。总之,Anderson等人的研究表明,粪便测试阳性与女性右侧晚期病变的相关性更高,而与男性无关。然而,当粪便测试阳性用于预测右侧晚期腺瘤时,他们无法在男性和女性中做到这一点。Mt-sDNA似乎可以预测男性和女性的右侧高级锯齿状息肉,但FIT只能预测女性。该研究确实表明,在粪便测试呈阳性的患者中,结肠息肉的解剖位置存在一些性别差异。然而,差异很小,即使在组合中确实显示出差异,与正确适应证和良好肠道准备的方案驱动的结肠镜检查相比,宽且重叠的95%置信区间似乎排除了任何日常实际应用。最后,我们想重申,男性和女性在结直肠癌方面的差异是公认的。关于息肉也有已知的性别差异;然而,我们认为这项研究并不能像作者所希望的那样,证明粪便阳性测试如何能够清楚地预测这种差异。Sanjiv Mahadeva是JGH Open的编辑委员会成员,也是本文的合著者。为了尽量减少偏倚,他被排除在所有与接受这篇文章发表相关的编辑决策之外。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JGH Open
JGH Open GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
3.40
自引率
0.00%
发文量
143
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信